Biologics Spine BioRestorative Reports Compelling Preliminary Data for FDA-Fast-Tracked BRTX-100 – an Autologous Stem Cell Therapy to Treat Chronic Lumbar Disc Disease byTim AllenJune 13, 2025
Financial BioRestorative Therapies Reports First Quarter 2025 Financial Results and Provides Business Update byTim AllenMay 14, 2025
Biologics Spine Phase 2 Trial of BRTX-100 in cLDD Continues to Generate Positive Preliminary Blinded Data byTim AllenMay 13, 2025
Biologics Spine BioRestorative Therapies Reports Positive Preliminary Phase 2 BRTX-100 Clinical Data byTim AllenNovember 13, 2024
Biologics Regulatory BioRestorative Therapies Receives Expanded Tissue License from New York State Department of Health byTim AllenNovember 5, 2024
Financial BioRestorative Therapies Reports Second Quarter 2024 Financial Results and Provides Business Update byJosh SandbergAugust 13, 2024
Financial BioRestorative Therapies Regains Compliance with Nasdaq Listing Rule 5250(c)(1); Reports First Quarter 2024 Financial Results byTim AllenJune 17, 2024
Regulatory Spine BioRestorative Therapies Announces FDA Clearance of Phase 2 BRTX-100 Clinical Study Protocol Amendment byTim AllenApril 16, 2024
Spine BioRestorative Therapies Partners with Galen Patient Recruitment to Accelerate Completion of Enrollment in Phase 2 Trial of BRTX-100 in Chronic Lumbar Disc Disease byTim AllenApril 8, 2024
Financial BioRestorative Therapies Announces Filing of 2023 Annual Report on Form 10-K byTim AllenApril 1, 2024
